Ayal Aizer, MD, MHS, discussed Alliance A071801 trial data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
News|Articles|August 27, 2026
Five Key Posters From the 2026 SNO/ASCO CNS Metastases Conference
Author(s)Cancer Network Staff
Fact checked by: Tim Cortese, Russ Conroy
New CNS metastasis data link gabapentin to fewer brain mets, spotlight trial barriers, and show promise for intrathecal therapy and osimertinib.
Advertisement
Advertisement
The 2026 SNO/ASCO CNS Metastases Conference brought together a multidisciplinary audience of neuro-oncologists, radiation oncologists, neurosurgeons, medical oncologists, and translational researchers to address the growing burden of brain and leptomeningeal metastases across tumor types. The meeting highlighted basic and translational research into central nervous system (CNS) tropism and the metastatic microenvironment alongside clinical sessions on precision neurosurgery, modern radiotherapy techniques, and the integration of systemic and CNS-directed therapies.
Related to this article
There is a gap in prospective data for radiation use in multiple myeloma, according to Alexandra Dreyfuss, MD, MS.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.
Brandon Mancini, MD, MBA, FACRO, discusses the presentations from ASTRO 2026 that may impact the future of prostate cancer, lung cancer, and other diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.
Nitin Ohri, MD, MS, discusses how his team manages toxicity and treatment tolerance as combination regimens grow more complex.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
Advertisement
Advertisement